OTCMKTS:RHHBY Roche (RHHBY) Stock Price, News & Analysis $39.11 +0.40 (+1.03%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$39.05▼$39.3950-Day Range$33.89▼$42.3352-Week Range$29.20▼$42.43Volume1.74 million shsAverage Volume2.33 million shsMarket Capitalization$267.12 billionP/E RatioN/ADividend Yield2.15%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort Interest Get Roche alerts: Email Address Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Roche Stock (OTCMKTS:RHHBY)Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.Read More RHHBY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RHHBY Stock News HeadlinesSeptember 15 at 2:47 AM | americanbankingnews.comRoche (OTCMKTS:RHHBY) Stock Rating Upgraded by Bank of AmericaSeptember 14 at 5:23 AM | americanbankingnews.comRoche (OTCMKTS:RHHBY) Lowered to "Sell" at Deutsche Bank AktiengesellschaftSeptember 15, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 13 at 2:27 AM | finanznachrichten.deF. Hoffmann-La Roche Ltd: FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapySeptember 13 at 2:27 AM | finance.yahoo.comFDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapySeptember 13 at 1:00 AM | globenewswire.comFDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapySeptember 12 at 9:21 PM | markets.businessinsider.comFDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer ImmunotherapySeptember 12 at 8:34 PM | reuters.comUS FDA approves injectable version of Roche's multiple sclerosis therapySeptember 15, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 12 at 8:01 AM | barrons.comRoche Setback Is Big for Eli Lilly, Novo Nordisk as Obesity Drug Battle Ramps UpSeptember 11, 2024 | finance.yahoo.comWhy Roche Holdings Stock Withered on WednesdaySeptember 11, 2024 | fool.comWhy Roche Holdings Stock Withered on WednesdaySeptember 11, 2024 | seekingalpha.comRoche falls while Novo, Lilly gain on weight-loss drug reportSeptember 11, 2024 | reuters.comRoche says early-stage obesity pill results were based on just six patientsSeptember 10, 2024 | finanznachrichten.deF. Hoffmann-La Roche Ltd: Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovationSeptember 10, 2024 | globenewswire.comRoche opens Pharma Research and Development Center in Basel to accelerate scientific innovationSeptember 9, 2024 | prnewswire.comLunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker TestingSeptember 9, 2024 | globenewswire.comStratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision DiagnosticsSee More Headlines Receive RHHBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPersonal Services Current SymbolOTCMKTS:RHHBY CUSIPN/A CIKN/A Webwww.roche.com Phone(161) 688-1111Fax41-0-61-691-9391Employees103,605Year Founded1896Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio14.59 P/E Growth3.63Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.75 Current Ratio1.35 Quick Ratio1.04 Sales & Book Value Annual Sales$65.37 billion Price / Sales4.09 Cash Flow$3.25 per share Price / Cash Flow12.02 Book Value$4.91 per share Price / Book7.97Miscellaneous Outstanding Shares6,830,000,000Free FloatN/AMarket Cap$267.12 billion OptionableNot Optionable Beta0.44 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Severin Schwan Ph.D. (Age 57)Executive Chairman Comp: $8.23MDr. Thomas Schinecker (Age 49)Chief Executive Officer Comp: $4.24MDr. Alan Hippe (Age 57)Chief Financial & Information Officer Comp: $4.5MDr. Bruno EschliHead of Investor RelationsMs. Claudia Bockstiegel (Age 60)General Counsel Ms. Pascale Schmidt (Age 51)Chief Compliance Officer Ms. Barbara Schadler (Age 62)Head of Group Communications Ms. Cristina A. Wilbur (Age 57)Chief People Officer Comp: $3.2MDr. Nicolas DunantHead of Group Media RelationsMr. Boris L. Zaitra (Age 52)Head of Group Business Development and M&A More ExecutivesKey CompetitorsChina Construction BankOTCMKTS:CICHYAirbusOTCMKTS:EADSYEssilorLuxottica Société anonymeOTCMKTS:ESLOYIberdrolaOTCMKTS:IBDRYAtlas CopcoOTCMKTS:ATLKYView All CompetitorsInstitutional OwnershipSaratoga Research & Investment ManagementSold 47,797 shares on 8/16/2024Ownership: 0.000%Cyrus J. Lawrence LLCSold 15,560 shares on 8/14/2024Ownership: 0.000%Hancock Whitney CorpSold 5,508 shares on 8/13/2024Ownership: 0.000%Altrius Capital Management IncBought 12,646 shares on 8/12/2024Ownership: 0.003%Hemenway Trust Co LLCSold 10,975 shares on 8/5/2024Ownership: 0.000%View All Institutional Transactions RHHBY Stock Analysis - Frequently Asked Questions How have RHHBY shares performed this year? Roche's stock was trading at $36.23 on January 1st, 2024. Since then, RHHBY stock has increased by 7.9% and is now trading at $39.11. View the best growth stocks for 2024 here. Does Roche have any subsidiaries? The following companies are subsidiaries of Roche: Inflazome, Stratos Genomics, Promedior, Spark Therapeutics, Tusk Therapeutics, Flatiron Health, Ignyta, and others. Who are Roche's major shareholders? Roche's top institutional investors include Saratoga Research & Investment Management, Cardinal Capital Management Inc., Boston Common Asset Management LLC and OLD National Bancorp IN. How do I buy shares of Roche? Shares of RHHBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RHHBY) was last updated on 9/15/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Turn Smartphones Into “Earnphones”?High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
